Country: Canada
Language: English
Source: Health Canada
ITRACONAZOLE
JAMP PHARMA CORPORATION
J02AC02
ITRACONAZOLE
10MG
SOLUTION
ITRACONAZOLE 10MG
ORAL
15G/50G
Prescription
AZOLES
Active ingredient group (AIG) number: 0123311001; AHFS:
APPROVED
2018-12-31
_JAMP Itraconazole Oral Solution (Itraconazole Oral Solution) _ _ _Page 1 of 63 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR JAMP ITRACONAZOLE ORAL SOLUTION Itraconazole oral solution solution, 10 mg/mL, oral Antimycotic for systemic use, triazole and tetrazole derivatives. JAMP Pharma Corporation 1310 rue Nobel Boucherville, Quebec J4B 5H3, Canada Date of Initial Authorization: December 31, 2018 Date of Revision: February 2, 2024 Control Number: 278552 _JAMP Itraconazole Oral Solution (Itraconazole Oral Solution) _ _ _Page 2 of 63 RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 02/2024 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ................................................................................................................................................ 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS .............................................................................................................. 4 1.1 Pediatrics ........................................................................................................ 4 1.2 Geriatrics ........................................................................................................ 4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ........................................................... 6 4 DOSAGE AND ADMINISTRATION ................................................................................ 6 4.1 Dosing Considerations .................................................................................... 6 4.2 Recommended Dose and Dosage Adjustment ............................................... 7 4. Read the complete document